The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 59 , ISSUE 1 ( January-March, 2017 ) > List of Articles

Original Article

A Study on Microalbuminuria in Patients with Chronic Obstructive Pulmonary Disease at a Tertiary Care Centre in North India

Anand Kumar, Sanjay Kumar Verma, Achal Mehrotra, Avdhesh Kumar, Sudhir Chaudhri, C.M. Verma

Keywords : COPD, Microalbuminuria, Lung, Hypoxia

Citation Information : Kumar A, Verma SK, Mehrotra A, Kumar A, Chaudhri S, Verma C. A Study on Microalbuminuria in Patients with Chronic Obstructive Pulmonary Disease at a Tertiary Care Centre in North India. Indian J Chest Dis Allied Sci 2017; 59 (1):17-21.

DOI: 10.5005/ijcdas-59-1-17

License: CC BY-NC 4.0

Published Online: 18-11-2022

Copyright Statement:  Copyright © 2017; The Author(s).


Background. In chronic obstructive pulmonary disease (COPD), systemic effects of the disease result in structural and/or biochemical alterations in structures or organs other than the lungs. Microalbuminuria (MAB) is an importantC risk factor for cardiovascular disease, and it may be seen due to hypoxaemia in patients with COPD. Objective. Present study was undertaken to find the presence of MAB in COPD and relationship of MAB with clinical and physiological parameters in stable patients with COPD. Methods. Sixty patients with COPD and 50 healthy controls were enrolled in the study. Spot urinary albumin/creatinine ratio, smoking history, spirometry, blood gases, body mass index, kidney function tests and BODE index (body-mass index, airflow obstruction, dyspnoea and exercise) were assessed. Frequency of MAB was compared between cases and controls. Results. Of 60 cases, 50 (83%) were males and 10 (17%) were females. In patients with COPD, MAB was found in all of them (100%) while in controls only 4 (10%) had MAB (p<0.0001). Conclusion. In the present study, MAB was seen in all the patients with COPD and MAB levels were significantly high in COPD cases compared with asymptomatic smokers with normal spirometry.

PDF Share
  1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
  2. Gibson GJ. Clinical Tests of Respiratory Function. 3rd edition. London: Hodder Arnold; 2009.
  3. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-85.
  4. Diercks GF, Van Boven AJ, Hillege JL, De Jong PE, Rouleau JL. The importance of microalbuminuria as a cardiovascular risk indicator: a review. Canadian J Cardiol 2002;18:525-35.
  5. Papaioannou GI, Seip RL, Grey NJ. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria. Am J Cardiol 2004;94:294-9.
  6. Mule G, Cottone S, Vadala A. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. J Intern Med 2004;256:22-29.
  7. Kohara K, Tabara Y, Tachibana R. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens ResC2004;27:471-7.
  8. Komurcuoglu A, Kalenci S, Kalenci D, Komurcuoglu B, Tibet G. Microalbuminuria in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 2003;59:269-72.
  9. Cogo A, Ciaccia A, Legorini C. Proteinuria in COPD patients with and without respiratory failure. Chest 2003;123:652-3.
  10. Polatli M, Cakir Q, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombol 2008;26:97-102.
  11. Casanova C, de Torres JP, Navarro J, Aguirre-Jaíme A, Toledo P. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:1004-10.
  12. Bulcun E, Ekici M, Ekici A, Kisa U. Microalbuminuria in chronic obstructive pulmonary disease. COPD 2013;10:186-92.
  13. GOLD: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2014).
  14. Celli BR, Mac Nee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS Position Paper. Eur Respir J 2004;23:932-46.
  15. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-6.
  16. Celli BR, Cote CG, Marin JM, Casanova C, M De Oca MM, Mendez RA, et al. The body-mass index, airûow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
  17. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-82.
  18. John M, Hussain S, Prayle A, Simms R, Cockcroft JR, Bolton CE. Target renal damage: the microvascular association of increased aortic stiffness in patients with COPD. Respir Res 2013;14:31-40.
  19. Kaysoydu E, Arslan S, Yýldýz G, Candan F. Factors related to microalbuminuria in patients with chronic obstructive pulmonary disease. Adv Clin Exp Med 2014;23:749-55.
  20. Mehmood K, Sofi FA. Microalbuminuria and hypoxemia in patients with COPD. J Pulm Respir Med 2015;5:4.
  21. Harris B, Klein R, Herold MJ, Hoffman EA, Ahmed FS, Jacobs DR Jr, et al. The association of systemic microvascular changes with lung function and lung density: a cross-sectional study. PLoS One 2012;7:e50224.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.